The short version of the findings
- Investigators mapped roughly 293,000 cells across the fetal-maternal interface to identify 27 distinct cell populations involved in severe preeclampsia.
- The study identified increased Leptin expression and Type I interferon signaling as potential biological bridges between placental distress and maternal illness.
- Severe preeclampsia affects an estimated 3% to 8% of pregnancies worldwide, and delivery remains the only definitive cure.
- Key cellular findings include mitochondrial dysfunction and oxidative stress in maternal immune cells, specifically in cases of early-onset disease.
The study at a glance
| Feature | Detail |
|---|---|
| Institution | University College London (UCL) and UCLH |
| Journal | Science Advances (published July 24, 2026) |
| Methods | Single-cell RNA sequencing and spatial transcriptomics |
| Cells analyzed | ~293,000, across 27 distinct cell populations |
| Sample | 20 pregnancies (10 severe preeclampsia, 10 controls) |
| Gestational age | 25 to 37 weeks |
Extensive cellular map reveals systemic maternal involvement
Severe preeclampsia has historically been understood primarily as a disease of the placenta. However, a landmark study published on July 24, 2026, in Science Advances suggests the condition is far more complex, involving the maternal immune system and tissues well beyond the fetal-maternal interface. Using advanced techniques like single-cell RNA sequencing and spatial transcriptomics, researchers at University College London (UCL) and University College London Hospitals (UCLH) analyzed approximately 293,000 individual cells.
The investigators looked at 20 pregnancies in total. This group included 10 women with severe preeclampsia and 10 healthy controls, with samples ranging from 25 to 37 weeks of gestation. By examining how cells behave in different compartments, the team identified 27 distinct cell populations. They observed that extravillous trophoblasts (EVTs), which are fetal cells that usually remodel uterine arteries to improve blood flow, were reduced in number and failed to penetrate deep uterine layers in affected pregnancies. This failure likely leads to reduced placental perfusion, causing the organ to become stressed and hypoxic.
Understanding preeclampsia and its biological markers
Preeclampsia is a hypertensive disorder specific to pregnancy that typically occurs after 20 weeks of gestation. It is defined by new-onset high blood pressure and the presence of protein in the urine (proteinuria). While it often remains mild, it can progress to a severe form that affects multiple organs and poses a life-threatening risk to both the mother and the baby. According to the World Health Organization (WHO), this condition impacts between 3% and 8% of pregnancies globally.
To understand the mechanism, think of the placenta as a power plant that must send electricity (nutrients and oxygen) to a city (the fetus). In preeclampsia, the wiring is faulty. The power plant begins to overheat and sends out smoke signals (stress hormones and inflammatory proteins) that eventually damage the city’s infrastructure and the surrounding environment.
In this study, one of those smoke signals was identified as FLT1, a gene that encodes a soluble receptor. Increased expression of this gene disrupts blood vessel growth, a hallmark of the disease. Another key signal is Leptin, a hormone usually associated with energy balance. Researchers found elevated leptin expression in placental trophoblasts, which they believe signals to maternal immune and endothelial cells, potentially linking placental dysfunction to systemic vascular inflammation.
Systemic metabolic and immune disturbances
The research highlighted a significant shift in maternal immune cells located outside the placenta. Monocytes and macrophages in women with severe preeclampsia showed elevated Type I interferon signaling. This pathway is typically used by the body to defend against viruses, but in this context, it appears to be a marker of severe disease detectable in maternal blood.
Along with immune changes, the study found signs of mitochondrial dysfunction and oxidative stress. These are states where the energy-producing centers of cells are impaired, leading to a buildup of reactive oxygen species. These findings were particularly pronounced in early-onset cases, which occur at or before 34 weeks of gestation.
Why precision mapping matters for future care
The current standard of care for preeclampsia focuses on managing symptoms, such as using medication to control blood pressure or prevent seizures. However, because these treatments do not address the underlying biology, delivery is frequently required early to protect the mother. This often leads to neonatal complications due to prematurity.
Identification of specific pathways like leptin signaling and mitochondrial dysfunction offers new molecular targets. Abdulla Al-Khan, MD, of Hackensack University Medical Center, noted that this research moves science closer to precision therapies that target the biology of the disease rather than just its clinical manifestations. Sara Hillman, a consultant at UCLH and UCL, suggested that these identified pathways might eventually allow for the use of existing treatments to address severe cases where the burden of mortality is highest.
Read the findings with the right caution
While the cellular mapping study provides a high-resolution view of the disease, it was based on a small sample size of 20 pregnancies. This means the findings are preliminary and require validation in much larger, multicenter studies before they can change how doctors treat patients.
It is also worth noting that the mapping study used samples ranging from 25 to 37 weeks. While it included early-onset cases, the molecular signatures of very early preeclampsia might differ from those occurring later in the third trimester.
The timeline for next steps
Researchers are now looking to explore whether the interferon signature identified in maternal blood can be used as a reliable biomarker. If this signature can be detected early through a standard blood test, it might allow for earlier intervention or closer monitoring of at-risk pregnancies. The team also plans to test the identified pathways in functional models and investigate whether existing drugs that target mitochondrial stress or interferon signaling could be repurposed for severe preeclampsia.
Sources:
- Medscape, “Study Offers New Clues to Severe Preeclampsia, Points to Future Treatment Targets” (https://www.medscape.com/viewarticle/study-offers-new-clues-severe-preeclampsia-points-future-2026a1000pb4)
- News-Medical, “Study discovers new therapeutic targets for severe preeclampsia” (https://www.news-medical.net/news/20260724/Study-discovers-new-therapeutic-targets-for-severe-preeclampsia.aspx)
Disclaimer: This article is for general information only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider about any medical condition or before making health decisions.